Article

Legacy neuropsychiatric benefit after semaglutide is linked to maximum achieved dose and independent of the maximum weight lost

2026-04-23

Abstract excerpt

GLP-1 receptor agonists have reshaped obesity therapeutics, but their impact on neuropsychiatric outcomes remains poorly characterized. From 29 million patients in a large federated data platform across the USA, including 489,785 semaglutide treated patients, we conducted an observational study integrating longitudinal neuropsychiatric outcomes. From this population, we assembled a cohort of 63,215 patients with b...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 30d627a3-8b22-57df-869c-d4fc9438de67
DOI: 10.64898/2026.04.16.26351060

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Legacy neuropsychiatric benefit after semaglutide is linked to maximum achieved dose and independent of the maximum weight lostDOI 10.64898/2026.04.16.26351060Read

Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotypingSemantic proximity Read

Neuro-Adverse Events Associated with GLP-1 Receptor Agonists: A Study Based on the FAERS Database and External Validation Using NHANES DatabaseSemantic proximity Read

Oral Wegovy Broadens Care Continuum Across First-Time GLP-Starters, High Cardiometabolic Burden GLP-Switchers, and Medicare-Age PatientsSemantic proximity Read

Influence of BMI-associated genetic variants and metabolic risk factors on weight loss with semaglutide: a longitudinal clinico-genomic cohort studySemantic proximity Read

Clinical efficacy landscaping in genetic obesity: A meta-analysis in Prader Willi syndrome (PWS)Semantic proximity Read

Efficacy and safety of semaglutide for obesity and hyperphagia in adults with Prader-Willi syndromeSemantic proximity Read

Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan.Semantic proximity Read

Neurosensory Risk After Semaglutide or Tirzepatide Is Lower Than Matched Antidiabetic and Bariatric Surgery Cohorts and Tracks Glycemic BurdenSemantic proximity Read

Obesity medication lorcaserin requires brainstem GLP-1 neurons to reduce food intake in miceSemantic proximity Read

Semaglutide is associated with stiffness improvement and broad liver benefits with distinct dose- and weight-linked patternsSemantic proximity Read

Pharmacogenomics of GLP-1 Receptor Agonists: Precision Medicine in the Age of Ozempic and MounjaroSemantic proximity Read